Perfil del fabricante
Cipla USA Inc.,
Compañía farmacéutica2 productos registrados
2
productos registrados
597.398
notificaciones totales
105
retiradas registradas
71,1%
graves en total
Productos
mostrando 2 de 2
| Producto | Aprobado | Notificaciones ↓ | Señal principal | Retiradas |
|---|---|---|---|---|
| 1982 | 592.039 | Diabetes mellitus tipo 2 | 100 | |
| 1982 | 5359 | Trastorno mineral y óseo de la enfermedad renal crónica | 5 |
Historial de retiradas · 50 registradas
| Fecha | Clase | Motivo | Empresa |
|---|---|---|---|
| 30 jul 2025 | II | Lack of Assurance of Sterility | GenoGenix LLC |
| 2 oct 2023 | II | Lack of Assurance of Sterility | Pine Pharmaceuticals, LLC |
| 17 ago 2023 | II | Lack of Assurance of Sterility:Lack of validation data for sanitization cycles | Central Admixture Pharmacy Services, Inc. |
| 17 ago 2023 | II | Lack of Assurance of Sterility:Lack of validation data for sanitization cycles | Central Admixture Pharmacy Services, Inc. |
| 11 ago 2023 | II | Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component. | Baxter Healthcare Corporation |
| 14 jul 2023 | II | Lack of assurance of sterility. Validation data for decontamination cycles is lacking. | Central Admixture Pharmacy Services, Inc. |
| 14 jul 2023 | II | Lack of assurance of sterility. Validation data for decontamination cycles is lacking. | Central Admixture Pharmacy Services, Inc. |
| 14 jul 2023 | II | Lack of assurance of sterility. Validation data for decontamination cycles is lacking. | Central Admixture Pharmacy Services, Inc. |
| 23 jun 2023 | I | Failed Stability Specification and Failed Impurities/Degradation Specifications: out of specification for inactive content ascorbic acid and MTHFRC-7impurity test | Lupin Pharmaceuticals Inc. |
| 28 abr 2023 | II | Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile. | Central Admixture Pharmacy Services, Inc. |
| 28 abr 2023 | II | Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile. | Central Admixture Pharmacy Services, Inc. |
| 28 abr 2023 | II | Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile. | Central Admixture Pharmacy Services, Inc. |
| 28 abr 2023 | II | Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile. | Central Admixture Pharmacy Services, Inc. |
| 22 dic 2022 | II | Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility. | Pharmacy Innovations |
| 22 dic 2022 | II | Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility. | Pharmacy Innovations |
| 18 may 2022 | II | Lack of Assurance of Sterility | Nephron Sterile Compounding Center LLC |
| 16 mar 2022 | III | Failed Impurities/Degradation Specifications: Out of Specification results for related substance. | Dr. Reddy's Laboratories, Inc. |
| 29 jul 2021 | II | Lack of Assurance of Sterility | Teva Pharmaceuticals USA |
| 26 abr 2021 | II | Lack of Assurance of Sterility | Teva Pharmaceuticals USA |
| 15 mar 2021 | II | CGMP Deviations: Intermittent exposure to temperature excursion during storage. | Cardinal Health Inc. |
| 19 jun 2019 | II | Lack of Assurance of Sterility | RXQ Compounding LLC |
| 13 feb 2018 | III | Presence of Foreign Tablets/Capsules | Nostrum Laboratories Inc |
| 22 feb 2017 | II | Labeling: Not Elsewhere Classified: Products may contain synthetic latex and/or natural latex. | Advanced Pharma Inc. |
| 18 nov 2016 | II | Lack of Assurance of Sterility - the firm is recalling select sterile drug products. | Cantrell Drug Company |
| 18 nov 2016 | II | Lack of Assurance of Sterility - the firm is recalling select sterile drug products. | Cantrell Drug Company |
| 18 jul 2016 | II | Penicillin Cross Contamination | GlaxoSmithKline, LLC |
| 7 jul 2016 | II | CGMP Deviations | Safecor Health, LLC |
| 20 jun 2016 | II | Lack of assurance of sterility: This recall includes of all unexpired lots medications containing Calcium Gluconate, Papaverine, Phentolamine, and /or Prostaglandin) due to unsubstantiated validation of beyond use dating. | W & C dba The Apothecary |
| 20 jun 2016 | II | Lack of assurance of sterility: This recall includes of all unexpired lots medications containing Calcium Gluconate, Papaverine, Phentolamine, and /or Prostaglandin) due to unsubstantiated validation of beyond use dating. | W & C dba The Apothecary |
| 18 dic 2015 | III | Labeling: Label mix-up. Docusate Sodium 100mg Softgels were mislabeled as Docusate Calcium 240mg. | National Vitamin Co Inc |
| 19 oct 2015 | II | Lack of Assurance of Sterility | Western Drug |
| 13 ago 2015 | II | Penicillin Cross Contamination and Presence of Foreign Substance. Product was contaminated with penicillin and foreign substances during manufacturing process. | GlaxoSmithKline, LLC. |
| 13 ago 2015 | II | Penicillin Cross Contamination and Presence of Foreign Substance. Product was contaminated with penicillin and foreign substances during manufacturing process. | GlaxoSmithKline, LLC. |
| 24 jul 2015 | II | Lack of Assurance of Sterility; all sterile human compounded drugs within expiry | JD & SN Inc., dba Moses Lake Professional Pharmacy |
| 28 may 2015 | II | Lack of Assurance of Sterility: Sterility of product is not assured. | Lincare, Inc. |
| 28 may 2015 | II | Lack of Assurance of Sterility: Sterility of product is not assured. | Lincare, Inc. |
| 8 ene 2015 | III | Subpotent Drug | Freedom Pharmaceuticals Inc |
| 17 dic 2014 | I | Non-Sterility: Out of specification results for the sterility test for microbial contamination. | Central Admixture Pharmacy Services, Inc. |
| 17 dic 2014 | I | Non-Sterility: Out of specification results for the sterility test for microbial contamination. | Central Admixture Pharmacy Services, Inc. |
| 17 dic 2014 | I | Non-Sterility: Out of specification results for the sterility test for microbial contamination. | Central Admixture Pharmacy Services, Inc. |
| 17 dic 2014 | I | Non-Sterility: Out of specification results for the sterility test for microbial contamination. | Central Admixture Pharmacy Services, Inc. |
| 17 dic 2014 | I | Non-Sterility: Out of specification results for the sterility test for microbial contamination. | Central Admixture Pharmacy Services, Inc. |
| 17 dic 2014 | I | Non-Sterility: Out of specification results for the sterility test for microbial contamination. | Central Admixture Pharmacy Services, Inc. |
| 17 dic 2014 | I | Non-Sterility: Out of specification results for the sterility test for microbial contamination. | Central Admixture Pharmacy Services, Inc. |
| 14 nov 2014 | II | Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin. | Attix Pharmaceuticals |
| 7 ago 2014 | I | Presence of Particulate Matter: particulate matter was found during the manufacturing process. | Baxter Healthcare Corp. |
| 14 abr 2014 | II | Cross Contamination with Other Products: Potential for contaminant on the cotton packaging inside the bottle. Chemical analysis of the contaminant found on the cotton was identified as a formulation of 4% Trimipramine methanesulfonate - a tricyclic antidepressant.. | Fresenius Medical Care Holdings, Inc. |
| 19 oct 2013 | II | Lack of Assurance of Sterility: All unexpired sterile compounded human and veterinary products are being recalled because they were compounded in the same environment and under the same practices as another product found to be non-sterile and therefore sterility cannot be assured. | Specialty Medicine Compounding Pharmacy |
| 9 ago 2013 | I | Non Sterility: Microbial contamination | Specialty Compounding, LLC |
| 26 jul 2013 | II | Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance | Beacon Hill Medical Pharmacy, P.C. |
Clase I = probabilidad razonable de daño grave · Clase II = temporal o reversible · Clase III = improbable que cause daño.
Estado de registro
Algunos productos de Cipla USA Inc., no están registrados por la FDA para uso humano. Para las sustancias no registradas (péptidos, SARM sin registro humano) no existe ningún proveedor legítimo para uso humano. La ausencia de una vía de aprovisionamiento es la información de seguridad.